Saturday, April 26, 2014

LAS VEGAS conference III Mantle cell

We first saw the Death of CHOP/R-CHOP in this disease
Now we see the death of Modified HyperCVAD
Today we see the rise of Ibrutinib-Rituxan in the firt setting of disease treatment
than only come Idelalisib
and ABT-199
and may be HyperCVAD
and if you think of Bendamustine-Rituxan (after failure of Ibritinib), do not forget Maintenance therapy with Rituxan (rather than Interferon)

(as a note, in Europe R-CHOP/R-DHAP but is there a need?) (trying to be controversial here, am I successful?)  CRBCM, we take things in strides!

BUT IN THIS DISEASE, BENDAMUSTIN -RITUXAN MAY BE BETTER THE R-CHOP!
*WATCH THE MIPI

SEE
 "

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Christian H. Geisler1"  GO TO ARTICLE
Post a Comment